RecruitingOBSERVATIONAL

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

This international registry is focused on Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN), a very rare type of blood cancer. Because it's so uncommon, doctors don't yet have a standard best way to treat it. The study aims to collect important information from many patients around the world. By putting together a large database, researchers hope to better understand how BPDCN presents, how different treatments work, and what factors might predict how someone will do. Ultimately, this information will help develop better treatment guidelines and improve care for people with this condition.

At a glance

Status

Recruiting

Sponsor

Immune Oncology Research Institute

Enrolment target

200

Start

01 Jul 2022

Estimated completion

01 Jul 2032

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

What is this study about?

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is a very rare form of blood cancer. While some progress has been made, doctors are still trying to figure out the best ways to treat it. Because so few people have BPDCN, it's hard for any single hospital or country to gather enough information to make clear recommendations.

This study is an international effort to bring together information about BPDCN from patients across the globe. Researchers want to create a large database to learn more about the condition, including how it's diagnosed, the types of treatments people receive, and how those treatments affect their health over time. They also want to identify factors that might help predict how the disease will progress.

The main goal is to use this gathered information to develop better, evidence-based recommendations for treating BPDCN in the future. By sharing knowledge and experiences on a global scale, the study aims to improve understanding and ultimately lead to better care for everyone affected by this rare cancer.

Key takeaways

It's an international study focusing on a rare blood cancer called BPDCN.
The goal is to improve understanding and treatment of BPDCN worldwide.
Participation involves sharing medical information from your existing records.
There are no new treatments or additional hospital visits required for this study.
Your contribution helps future patients with this rare condition.

Who may be eligible?

This study is looking for people who have been diagnosed with a rare blood cancer called Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).

If you have received this diagnosis, you might be able to take part. For prospective patients, your doctors will talk to you about the study and ask you to sign a consent form, which means you agree to share your health information for the research.

There are no specific reasons given that would stop someone from joining the study, as long as they have the BPDCN diagnosis and agree to participate by signing the consent form.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Have I been diagnosed with Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)?
Am I willing to have my medical information shared for this research?
Have I signed an informed consent form (if applicable as a new patient)?
Am I comfortable with my data being used to help improve future care for BPDCN?

Answer every question to see your result.

What does participation involve?

This study is an international registry, which means it collects existing medical information rather than asking you to do extra tests or take new medications. If you decide to take part, your medical team will collect information about your diagnosis, the treatments you've received, and how your health has progressed. This will involve filling out questionnaires about details such as your characteristics, the specifics of your BPDCN, your treatment journey, and how you are doing. The information is collected by your national study group or participating hospital, and your privacy is protected. There are no additional visits or follow-up appointments required specifically for this study.

Potential risks and benefits

A potential benefit of taking part is contributing valuable information that could help improve the understanding and treatment of BPDCN for future patients. While there are no direct medical benefits to you personally, your contribution is very important for medical research. There are no known physical risks of participating, as this study only involves collecting existing medical information. Your decision to participate is entirely voluntary, and you have the right to withdraw your consent at any time without it affecting your medical care.

Locations (20)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

Sylvester Comprehensive Cancer Center, University of Miami
Verified postcode
Miami, United States· Recruiting
Moffitt Cancer Center
Verified postcode
Tampa, United States· Recruiting
Seattle Children's Cancer and Blood Disorders Center
Verified postcode
Seattle, United States· Recruiting
Hematology Center named after prof. R. Yeolyan
Verified postcode
Yerevan, Armenia· Recruiting
University of Calgary
Verified postcode
Calgary, Canada· Recruiting
Children's Hospital of Eastern Ontario, University of Ottawa
Verified postcode
Ottawa, Canada· Recruiting
Cyprus Society of Haematology
Verified postcode
Nicosia, Cyprus· Recruiting
Oncology Center, Mansoura University Faculty of Medicine
Verified postcode
Al Mansurah, Egypt· Recruiting
M. Iashvili Children's Central Hospital
Verified postcode
Tbilisi, Georgia· Recruiting
Department of Medical Oncology, Dr. B.R.A Institute Rotary Cancer Hospital, All India Institute of Medical Sciences
Verified postcode
New Delhi, India· Recruiting
Pediatric Hematology Oncology, Children's Welfare Teaching Hospital, Medical City, College of Medicine, University of Baghdad
Verified postcode
Baghdad, Iraq· Recruiting
University of Perugia - Azienda Ospedaliera Perugia
Verified postcode
Perugia, Italy· Recruiting

Common questions

What is BPDCN?

BPDCN stands for Blastic Plasmacytoid Dendritic Cell Neoplasm, which is a very rare type of blood cancer.

Why is this study important?

Because BPDCN is so rare, doctors need to gather information from many patients worldwide to better understand the disease and find the best ways to treat it.

Do I have to take any new medicines?

No, this study is a registry, which means it collects information about your existing care; you won't be asked to take new medicines or undergo extra procedures.

What kind of information will be collected?

Information about your diagnosis, treatments you've received, and how you've responded to them will be collected from your medical records.

Will my personal details be kept private?

Yes, all personal information will be handled with strict confidentiality by the researchers.

How to find out more

Astghik Voskanyan, MD

astghikvos@gmail.com +374 10 28 38 00 Official trial record

Always speak to your GP or specialist before deciding to take part in a study.